Clinical trials: Conbercept
Retinoblastoma
A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Injection in the Treatment of Retinoblastoma
This prospective, multi-center, open single-arm Phase II clinical trial is designed to investigate the efficacy and safety of intravenous chemotherapy combined with Conbercept intravitreal injection in the treatment of…
- Trial name
- NCT04990271
- Testing
- Conbercept ophthalmic injection
- Where
- 5 sites in China
- Volunteers
- 92 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Wet Age-related Macular Degeneration (wAMD)
Safety Evaluation of China Patients: Long-term Treatment Outcome of Conbercept Ophthalmic Injection in Real Word（STONE）
This is a post-marketing drug safety monitoring study in a prospective manner, and data collection will be performed in a registration-follow-up manner.
- Trial name
- NCT03054818
- Where
- 49 sites in China
- Volunteers
- 4,000 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Diabetes Mellitus, Type 2, Macular Edema
Effects of Adding Triamcinolone Acetonide to Conbercept Treatment for Refractory Diabetic Macular Edema (CONTE)
This study aimed to compare intravitreous conbercept alone with conbercept plus intravitreous triamcinolone acetonide in DME eyes which showed limited response to anti-VEGF treatment after one injection.
- Trial name
- CONTE (NCT04627402)
- Testing
- Conbercept and TA, Conbercept
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Proliferative Diabetic Retinopathy
Conbercept vs Panretinal Photocoagulation for the Management of Proliferative Diabetic Retinopathy
Panretinal photocoagulation (PRP) has been the standard treatment for Proliferative diabetic retinopathy (PDR) since the Diabetic Retinopathy Study demonstrated its benefit nearly 40 years ago,but PRP has inevitable adverse…
- Trial name
- NCT02911311
- Testing
- intravitreal injection of conbercept, PRP
- Where
- China
- Volunteers
- 226 people
- Sponsor
- Sun Yat-sen University
Retinopathy of Prematurity (ROP)
Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy
Evaluating the Optimal Effective Dose and Safety of Conbercept in Treating Retinopathy of Prematurity (ROP)
- Trial name
- NCT06717412
- Testing
- Conbercept
- Where
- 3 sites in China
- Volunteers
- 146 people
- Sponsor
- Wang Yusheng
Proliferative Diabetic Retinopathy
Efficacy and Safety Comparison of IVR and IVC Before Vitrectomy in Proliferative Diabetic Retinopathy
Proliferative diabetic retinopathy (PDR) is the most common causes of irreversible blindness in diabetic retinopathy (DR).Although pars plana vitrectomy (PPV) is the cornerstone for treatment of advanced PDR, related…
- Trial name
- NCT05414149
- Testing
- preoperative intravitreal injections of ranibizumab or conbercept
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Peking University People's Hospital
Polypoid Choroidal Vasculopathy (PCV)
Phase IV Clinical Trial (STAR Study) Extension Study of Conbercept Ophthalmic Injection for Treatment of Polypoid Choroidal Vasculopathy
To explore efficacy and safety of 0.5 mg conbercept ophthalmic injection for long-term treatment of polypoid choroidal vasculopathy (PCV) subjects.
- Trial name
- NCT03244657
- Testing
- conbercept ophthalmic injection （0.5mg）
- Where
- 30 sites in China
- Volunteers
- 200 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Neovascular Glaucoma
The Effect of Conbercept Injection Through Different Routes for Neovascular Glaucoma
The neovascular glaucoma (NVG) is a refractory type of secondary glaucoma and often lead to frustrated treatment and blindness. It has been confirmed high levels of vascular endothelial growth factor (VEGF) in NVG.
- Trial name
- NCT03154892
- Testing
- Intracameral injection, Intravitreal injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
Early Proliferative Diabetic Retinopathy
Intravitreal Conbercept After Vitrectomy
To evaluate the safety and efficacy of intravitreal conbercept after vitrectomy for the management of early-stage proliferative diabetic retinopathy (PDR).
- Trial name
- NCT03426540
- Testing
- Conbercept
- Volunteers
- 50 people
- Sponsor
- Tianjin Medical University Eye Hospital
Diabetic Macular Edema, Diabetic Retinopathy
Prophylactic Effect of Conbercept Intravitreal Injection at the Conclusion of Cataract Surgery for Diabetic Macular Edema
Diabetic macular edema (DME) is an important cause of central vision impairment among people with diabetic retinopathy (DR), which can have a significant adverse effect on daily activities and quality of life.
- Conditions
- Diabetic Macular Edema, Diabetic Retinopathy, Cataract Diabetic
- Trial name
- NCT04668703
- Testing
- Conbercept intravitreal injection
- Volunteers
- 40 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Neovascular Age-related Macular Degeneration
Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1)
The purpose of this clinical study is to evaluate the efficacy and safety of two different levels of conbercept intravitreal (IVT) injection as compared to the approved vascular endothelial growth factor (VEGF) antagonist active…
- Trial name
- NCT03577899
- Testing
- 0.5 mg Conbercept Intravitreal Injection, 1.0 mg Conbercept Intravitreal Injection, 2.0 mg Aflibercept Intravitreal Injection
- Where
- 179 sites in United States, Argentina and 20 more
- Volunteers
- 1,157 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Severe Nonproliferative Diabetic Retinopathy, Diabetic Retinopathy
PRP vs PRP+IVC for Severe nPDR
The randomized clinical trial aims to compare the therapeutic effects between panretinal photocoagulation(PRP) and PRP combined with intravitreal conbercept (IVC) injection in severe nPDR with/without diabetic macular edema…
- Conditions
- Severe Nonproliferative Diabetic Retinopathy, Diabetic Retinopathy, Diabete Mellitus
- Trial name
- NCT03863535
- Testing
- Conbercept, Panretinal coagulation
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Ruijin Hospital
Very Low Vision Secondary to Wet Age-related Macular Degeneration
An Open, Single-center, Safety and Efficacy Study of Conbercept in Patients With Very Low Vision Secondary to Wet Age-related Macular Degeneration (wAMD)
This study is designed to evaluate the effect of Conbercept therapy on visual acuity and anatomic outcomes and safety observed in subjects with very low vision secondary to wet age-related macular degeneration.
- Trial name
- LAMP (NCT02098720)
- Testing
- Conbercept
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Retinal Vein Occlusion
Aqueous Humor Proteome in Retinal Vein Occlusion With Macular Edema
the goal of this observational study is to the find the molecular mechanisms underlying the prognosis process of Retinal vein occlusion in patients with retinal vein occlusion .
- Trial name
- NCT07106268
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University Eye Hospital
Idiopathic Choroidal Neovascularization
Intravitreal Conbercept for Idiopathic Choroidal Neovascularization
The purpose of this study is to evaluate the efficacy of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy as primary treatment for ICNV.
- Trial name
- NCT02857517
- Testing
- conbercept
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Jiao Mingfei
Branch Retinal Vein Occlusion, Macular Edema
Conbercept Ophthalmic Injection for Patients With Macular Edema Caused by Branch Retinal Vein Occlusion
The purpose of this study is to verify the efficacy and safety of intravitreal injection of conbercept in patients with macular edema (ME) caused by branch retinal vein occlusion (BRVO).
- Trial name
- BRAVE (NCT03108352)
- Testing
- Conbercept ophthalmic injection
- Where
- 31 sites in China
- Volunteers
- 255 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Corneal Neovascularization
An Exploratory Clinical Trial Evaluating the Tolerability and Efficacy of KH906 in Patients With Corneal Neovascularization
The first stage of this study will evaluates the tolerability of different concentrations of Conbercept eye drop to patients with corneal neovascularization.
- Trial name
- NCT04215393
- Testing
- Conbercept eye drop
- Where
- 2 sites in China
- Volunteers
- 39 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Polypoidal Choroidal Vasculopathy, Conbercept
Conbercept for Polypoidal Choroidal Vasculopathy（START Study）
1. To evaluate the effectiveness of Conbercept for PCV patients. 2. To describe the characteristics of PCV. 3. To describe the adverse events (AE) of Conbercept in the treatment of PCV. 4.
- Trial name
- NCT05229237
- Testing
- Conbercept
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Peking Union Medical College Hospital
Diabetic Macular Edema, Pars Plana Vitrectomy
Microinvasive Pars Plana Vitrectomy Combined ILM Peeling Versus Anti-VEGF Intravitreal Injection for Treatment-naïve Diabetic Macular Edema
Diabetic macular edema (DME) is the main cause of vision loss in patients with diabetes. At present, anti-vascular endothelial growth factor (VEGF) intravitreal injection is the first-line therapy for DME, nevertheless, some…
- Conditions
- Diabetic Macular Edema, Pars Plana Vitrectomy, Conbercept
- Trial name
- NCT05728476
- Testing
- Vitrectomy combined with ILM peeling, Conbercept intravitreal injection
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Tianjin Medical University Eye Hospital
Macular Edema, Central Retinal Vein Occlusion
Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion
This study evaluates the efficacy and safety of Conbercept ophthalmic injection. This is a multi-center, randomized, double-masked, placebo-controlled phase III clinical study.
- Trial name
- CRAVE (NCT03223714)
- Testing
- Conbercept Ophthalmic Injection
- Where
- 27 sites in China
- Volunteers
- 242 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.